US Edition
Published • loading... • Updated
AD/PD 2026: J&Js anti-tau drug posdinemab fails in early Alzheimer’s disease
Summary by Clinical Trials Arena
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
AD/PD 2026: J&Js anti-tau drug posdinemab fails in early Alzheimer’s disease
J&J was keen to highlight that these trial results do not invalidate tau as a therapeutic target for Alzheimer’s disease; the trial helps further understanding of tau pathology.The post AD/PD 2026: J&Js anti-tau drug posdinemab fails in early Alzheimer’s disease appeared first on Clinical Trials Arena.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
